Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec, a biotechnology firm that manufactures, discovers, develops and commercializes therapies, has reported total revenues of $1.20bn for the second quarter ended 30 June 2011, compared to $1.21bn for the same period in 2010.
Subscribe to our email newsletter
Biogen Idec‘s net income was $304.49m, compared to $294.64m for the same period in the prior year.
The company’s income from operations was $410.81m for the second quarter ended 30 June 2011, as compared to $395.88m for the same period in 2010.
For the six months ended 30 June 2011 total revenue were $2.41bn, compared to $2.32bn for the same period in 2010.
Net income was $612.81m for the six months ended 30 June 2011, as compared to $514.64m for the same period prior year.
For the six months ended 30 June 2011, the company’s income from operations were $827.09m , as compared to $699.56 for the same period in 2010.
Biogen Idec CEO George Scangos said this quarter, they were excited by the European Commission’s approval of the inclusion of JCV antibody status as an additional PML risk factor in TYSABRI labeling, as well as the conditional approval for FAMPYRA.